AbbVie Inc. Stock Underperforms Friday When Compared To Competitors

Realty Income Corp

Change company Symbol lookup

Select an option...

O Realty Income Corp

DMO Western Asset Mortgage Opportunity Fund Inc

TEX Terex Corp

JEPI JPMorgan Equity Premium Income ETF

SPYD SPDR® Portfolio S&P 500 High Dividend ETF

AAPL Apple Inc

VYM Vanguard High Dividend Yield Index Fund ETF Shares

DGRO iShares Core Dividend Growth ETF

DIVO Amplify CWP Enhanced Dividend Income ETF

SCHD Schwab U.S. Dividend Equity ETF™

Real Estate : Equity Real Estate Investment Trusts (REITs) | Large Cap Blend

Company profile

Realty Income Corporation is a real estate investment trust. The Company is engaged in acquiring and managing single-unit freestanding commercial properties under a long-term net lease agreement with its commercial clients. The Company owns and operates diversified portfolio of over 11,400 commercial properties. The Company’s properties are leased to over 1,100 different clients who operate in approximately 72 separate industries throughout all 50 states, as well as Puerto Rico, the United Kingdom and Spain. Its properties are leased to retail and industrial clients that have a service, non-discretionary and/or low-price-point component to their business. The Company’s property types include retail, industrial, and agriculture.

AbbVie Inc. Stock Underperforms Friday When Compared To Competitors

4:33 pm ET October 28, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) slipped 3.84% to $147.61 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 2.46% to 3,901.06 and the Dow Jones Industrial Average rising 2.59% to 32,861.80. The stock's fall snapped a two-day winning streak. AbbVie Inc. closed $28.30 short of its 52-week high ($175.91), which the company achieved on April 8th.

The stock underperformed when compared to some of its competitors Friday, as Pfizer Inc. (PFE) rose 3.69% to $47.43, Eli Lilly & Co. (LLY) rose 1.00% to $359.90, and AstraZeneca PLC ADR (AZN.LN) rose 1.91% to $58.71. Trading volume (10.8 M) eclipsed its 50-day average volume of 5.3 M.

Data source: Dow Jones Market Data, FactSet. Data compiled October 28, 2022.

(END) Dow Jones Newswires

October 28, 2022 16:33 ET (20:33 GMT)